Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study

Jae Seung Chang, Tae Ho Kim, Tuyet Thi Nguyen, Kyu Sang Park, Nahyun Kim, In Deok Kong

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aim: Myokines are peptides released by the skeletal muscle, and have gained popularity as potential biomarkers for sarcopenia. Irisin is a recently identified myokine, but its role in pathological sarcopenia remains unclear. We investigated the validity and accuracy of circulating irisin levels as a potential biomarker for sarcopenia. Methods: We evaluated the anthropometrics, body composition, sarcopenia-related parameters and serum irisin levels of 715 community-dwelling Koreans. Sarcopenia was determined on the basis of the clinical diagnostic criteria of muscle atrophy and weakness, which were proposed by the Asian Working Group for Sarcopenia. Results: Circulating irisin levels were correlated with appendicular lean mass/height 2 (r men = 0.275; r women = 0.321) and handgrip strength (r men = 0.219; r women = 0.312) in both sexes (all P < 0.01). Furthermore, the mean circulating irisin levels were lower in the sarcopenia group than in the normal group (all P < 0.05). In the logistic regression models, the association between serum irisin concentration and incident sarcopenia persisted even after adjusting for potential confounders, such as sex, age and fat indices (odds ratio 0.20, 95% CI 0.07–0.60; P for trend <0.01). The predictive values of serum irisin for sarcopenia were <1.0 μg/mL in men and <1.16 μg/mL in women, with the area under the receiver operating characteristic curves of 0.87 (95% CI 0.77–0.99) and 0.68 (95% CI 0.55–0.81), respectively (all P < 0.01). Conclusions: A low level of circulating irisin is a sensitive marker for muscle weakness and atrophy. Irisin is a potential biomarker for muscle dysfunction that could help predict the onset of sarcopenia and provide new avenues for monitoring age-related muscle changes. Geriatr Gerontol Int 2017; 17: 2266–2273.

Original languageEnglish
Pages (from-to)2266-2273
Number of pages8
JournalGeriatrics and Gerontology International
Volume17
Issue number11
DOIs
Publication statusPublished - 2017 Nov

Fingerprint

Sarcopenia
Biomarkers
community
working group
popularity
incident
diagnostic
recipient
Group
logistics
Muscular Atrophy
monitoring
Muscle Weakness
regression
trend
Logistic Models
Serum
Independent Living
Muscles
Body Composition

All Science Journal Classification (ASJC) codes

  • Health(social science)
  • Gerontology
  • Geriatrics and Gerontology

Cite this

@article{75479b32356c488781cde8979dc233f7,
title = "Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study",
abstract = "Aim: Myokines are peptides released by the skeletal muscle, and have gained popularity as potential biomarkers for sarcopenia. Irisin is a recently identified myokine, but its role in pathological sarcopenia remains unclear. We investigated the validity and accuracy of circulating irisin levels as a potential biomarker for sarcopenia. Methods: We evaluated the anthropometrics, body composition, sarcopenia-related parameters and serum irisin levels of 715 community-dwelling Koreans. Sarcopenia was determined on the basis of the clinical diagnostic criteria of muscle atrophy and weakness, which were proposed by the Asian Working Group for Sarcopenia. Results: Circulating irisin levels were correlated with appendicular lean mass/height 2 (r men = 0.275; r women = 0.321) and handgrip strength (r men = 0.219; r women = 0.312) in both sexes (all P < 0.01). Furthermore, the mean circulating irisin levels were lower in the sarcopenia group than in the normal group (all P < 0.05). In the logistic regression models, the association between serum irisin concentration and incident sarcopenia persisted even after adjusting for potential confounders, such as sex, age and fat indices (odds ratio 0.20, 95{\%} CI 0.07–0.60; P for trend <0.01). The predictive values of serum irisin for sarcopenia were <1.0 μg/mL in men and <1.16 μg/mL in women, with the area under the receiver operating characteristic curves of 0.87 (95{\%} CI 0.77–0.99) and 0.68 (95{\%} CI 0.55–0.81), respectively (all P < 0.01). Conclusions: A low level of circulating irisin is a sensitive marker for muscle weakness and atrophy. Irisin is a potential biomarker for muscle dysfunction that could help predict the onset of sarcopenia and provide new avenues for monitoring age-related muscle changes. Geriatr Gerontol Int 2017; 17: 2266–2273.",
author = "Chang, {Jae Seung} and Kim, {Tae Ho} and Nguyen, {Tuyet Thi} and Park, {Kyu Sang} and Nahyun Kim and Kong, {In Deok}",
year = "2017",
month = "11",
doi = "10.1111/ggi.13030",
language = "English",
volume = "17",
pages = "2266--2273",
journal = "Geriatrics and Gerontology International",
issn = "1444-1586",
publisher = "Japan Geriatrics Society",
number = "11",

}

Circulating irisin levels as a predictive biomarker for sarcopenia : A cross-sectional community-based study. / Chang, Jae Seung; Kim, Tae Ho; Nguyen, Tuyet Thi; Park, Kyu Sang; Kim, Nahyun; Kong, In Deok.

In: Geriatrics and Gerontology International, Vol. 17, No. 11, 11.2017, p. 2266-2273.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Circulating irisin levels as a predictive biomarker for sarcopenia

T2 - A cross-sectional community-based study

AU - Chang, Jae Seung

AU - Kim, Tae Ho

AU - Nguyen, Tuyet Thi

AU - Park, Kyu Sang

AU - Kim, Nahyun

AU - Kong, In Deok

PY - 2017/11

Y1 - 2017/11

N2 - Aim: Myokines are peptides released by the skeletal muscle, and have gained popularity as potential biomarkers for sarcopenia. Irisin is a recently identified myokine, but its role in pathological sarcopenia remains unclear. We investigated the validity and accuracy of circulating irisin levels as a potential biomarker for sarcopenia. Methods: We evaluated the anthropometrics, body composition, sarcopenia-related parameters and serum irisin levels of 715 community-dwelling Koreans. Sarcopenia was determined on the basis of the clinical diagnostic criteria of muscle atrophy and weakness, which were proposed by the Asian Working Group for Sarcopenia. Results: Circulating irisin levels were correlated with appendicular lean mass/height 2 (r men = 0.275; r women = 0.321) and handgrip strength (r men = 0.219; r women = 0.312) in both sexes (all P < 0.01). Furthermore, the mean circulating irisin levels were lower in the sarcopenia group than in the normal group (all P < 0.05). In the logistic regression models, the association between serum irisin concentration and incident sarcopenia persisted even after adjusting for potential confounders, such as sex, age and fat indices (odds ratio 0.20, 95% CI 0.07–0.60; P for trend <0.01). The predictive values of serum irisin for sarcopenia were <1.0 μg/mL in men and <1.16 μg/mL in women, with the area under the receiver operating characteristic curves of 0.87 (95% CI 0.77–0.99) and 0.68 (95% CI 0.55–0.81), respectively (all P < 0.01). Conclusions: A low level of circulating irisin is a sensitive marker for muscle weakness and atrophy. Irisin is a potential biomarker for muscle dysfunction that could help predict the onset of sarcopenia and provide new avenues for monitoring age-related muscle changes. Geriatr Gerontol Int 2017; 17: 2266–2273.

AB - Aim: Myokines are peptides released by the skeletal muscle, and have gained popularity as potential biomarkers for sarcopenia. Irisin is a recently identified myokine, but its role in pathological sarcopenia remains unclear. We investigated the validity and accuracy of circulating irisin levels as a potential biomarker for sarcopenia. Methods: We evaluated the anthropometrics, body composition, sarcopenia-related parameters and serum irisin levels of 715 community-dwelling Koreans. Sarcopenia was determined on the basis of the clinical diagnostic criteria of muscle atrophy and weakness, which were proposed by the Asian Working Group for Sarcopenia. Results: Circulating irisin levels were correlated with appendicular lean mass/height 2 (r men = 0.275; r women = 0.321) and handgrip strength (r men = 0.219; r women = 0.312) in both sexes (all P < 0.01). Furthermore, the mean circulating irisin levels were lower in the sarcopenia group than in the normal group (all P < 0.05). In the logistic regression models, the association between serum irisin concentration and incident sarcopenia persisted even after adjusting for potential confounders, such as sex, age and fat indices (odds ratio 0.20, 95% CI 0.07–0.60; P for trend <0.01). The predictive values of serum irisin for sarcopenia were <1.0 μg/mL in men and <1.16 μg/mL in women, with the area under the receiver operating characteristic curves of 0.87 (95% CI 0.77–0.99) and 0.68 (95% CI 0.55–0.81), respectively (all P < 0.01). Conclusions: A low level of circulating irisin is a sensitive marker for muscle weakness and atrophy. Irisin is a potential biomarker for muscle dysfunction that could help predict the onset of sarcopenia and provide new avenues for monitoring age-related muscle changes. Geriatr Gerontol Int 2017; 17: 2266–2273.

UR - http://www.scopus.com/inward/record.url?scp=85017452800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017452800&partnerID=8YFLogxK

U2 - 10.1111/ggi.13030

DO - 10.1111/ggi.13030

M3 - Article

C2 - 28394089

AN - SCOPUS:85017452800

VL - 17

SP - 2266

EP - 2273

JO - Geriatrics and Gerontology International

JF - Geriatrics and Gerontology International

SN - 1444-1586

IS - 11

ER -